Developer of ortho-biological technology intended to provide bone graft substitute for use in spinal fusion surgery and
Developer of ortho-biological technology intended to provide bone graft substitute for use in spinal fusion surgery and other orthopedic procedures.
Surgical Devices📍 Westminster, COFounded 2001
Current Valuation
$700M
as of 2022-Q1
PRIVATE
QL Price
$700M
0% vs last round
QuantLogix's current estimate for Cerapedics, published 2026-09-27 — in line with the last disclosed round of $700M (2022-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$700M
2022-Q1
weight 0.04
How this price has held up
No round has priced for Cerapedics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Cerapedics, 2026-09-27 (6000d7f1e6b293e2).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Cerapedics going public?
No. Cerapedics is private and has not filed to go public. There is no S-1 on file.
What is Cerapedics' valuation in 2026?
Cerapedics is valued at $700M as of 2022-Q1, set by its Series F ($25M, Feb 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Cerapedics filed an S-1?
No public S-1 is on file for Cerapedics.
How much has Cerapedics raised?
Cerapedics has raised $157.65M in total, most recently a Series F of $25M in Feb 2022.
Is Cerapedics publicly traded — can you buy Cerapedics stock?
No. Cerapedics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Cerapedics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2001
HQ
Westminster, CO
Employees
206
Total Raised
$157.65M
Last Round
Series F — $25M (Feb 2022)
IPO Status
private
Fundraising Status
Series F · $25M · 4y 7mo ago
privateTotal raised $157.65M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F
$25M
Feb 2022
—
$700M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
1 active · 0 recruiting
Focus areas
Degenerative Disc Disease
Intervertebral Disk Degeneration
Latest trial start
2022-01
Name-verified against lead sponsor "CeraPedics, Inc" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
7
via careers page
Product-build share
43%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 43% builders vs 57% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Request Medical InformationHealth insurance: Comprehensive and competitive medical, dental, and vision plan[Request Medical Information](https://www.cerapedics.com/mirf)Skip to main contentfinancial benefitsPEOPLE AT CERAPEDICS
Counted from Cerapedics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.